Cansino Biologics Inc. launched its second pre-revenue share offering on Aug. 13, reaping ¥5.2 billion ($749 million) from Shanghai’s STAR market. Trading under the ticker 688185, its shares surged 87.5% to close at ¥393 on the first trading day. The company, currently developing 16 vaccine candidates for 13 infectious diseases, has grabbed headlines this year for its COVID-19 vaccine candidate, Ad5-nCoV, which is due to enter phase III trials in Saudi Arabia shortly.

With an eye toward launching its first product, Mobilion Systems Inc. has revealed a $35 million series B funding round led by Amoon. Todd Sone, partner at Amoon who also is joining the company’s board, highlighted the duo’s common vision to develop technologies that offer high resolution and speed.

Months after revealing a U.S. FDA nod for the Rhinaer Stylus to treat chronic rhinitis, Aerin Medical Inc. reported the closing of a $48 million equity financing. In addition, the company revealed that Matt Brokaw, who has deep experience in the ear, nose and throat (ENT) space, has come on board as president and CEO.

Tech-enabled diabetes and chronic conditions management company Cecelia Health has secured $13 million in a series B financing led by Rittenhouse Ventures and Endo Investors. Other participants in the round included Boston Millennia Partners, SustainVC and G100 Capital. The funds will be used to speed and further scale adoption of the company’s coaching and telemedicine tools and to build out digital health capabilities.